Similar Articles |
|
BusinessWeek November 21, 2005 Gene G. Marcial |
Salix Pharmaceuticals: What The Gut Tells You The small fry in gastrointestinal drugs is a pure play in that growing market. |
The Motley Fool February 24, 2011 Brian D. Pacampara |
Salix Pharmaceuticals Shares Plunged: What You Need to Know Shares of Salix Pharmaceuticals plummeted more than 20% after the company said it expects the Food and Drug Administration to deny its bid to gain expanded approval for its gastrointestinal antibiotic Xifaxan. |
The Motley Fool May 10, 2011 Frank Vinluan |
Salix Sued by Partner for "Breach" Over HIV-Associated Drug Who will take this blockbuster drug to market? |
The Motley Fool February 25, 2011 Brian Orelli |
When the Companies Know, Investors Should, Too Why don't more companies preannounce FDA rejections? |
The Motley Fool February 26, 2011 Brian Orelli |
FDA Applications and a Look Ahead It isn't pretty. |
The Motley Fool December 21, 2004 Charly Travers |
Invest With Fewer Side Effects Averse to risk? Check out these nontraditional drug companies: Biogen Idec... Elan... Salix Pharmaceuticals... Atrix Laboratories... etc. |
The Motley Fool November 30, 2010 Brian Orelli |
Soros Is Buying Health Care. Should You? Some but not all of his picks look good to me. |
Chemistry World March 25, 2015 Phillip Broadwith |
Valeant heads off Endo bid for Salix Valeant has flexed its acquisitive muscles to head off a rival bid for gastroenterology specialist Salix Pharmaceuticals. |
The Motley Fool December 20, 2011 Brian D. Pacampara |
Salix Pharmaceuticals Shares Popped: What You Need to Know Shares of drugmaker Salix Pharmaceuticals climbed as high as 10.5% on Tuesday after the company reported positive phase-3 data for an oral version of its constipation treatment, Relistor. |
Chemistry World February 23, 2015 Phillip Broadwith |
Valeant to buy Salix for $14.5bn Serial acquirer Valeant has agreed to buy gastroenterology specialist Salix Pharmaceuticals for $14.5 billion |